{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:27:02Z","timestamp":1793230022791,"version":"4.5.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM122196-02A1"],"award-info":[{"award-number":["GM122196-02A1"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["3R43NS107079-01S1"],"award-info":[{"award-number":["3R43NS107079-01S1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["OT2TR003441"],"award-info":[{"award-number":["OT2TR003441"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011070","name":"Research Opportunities Initiative, University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U01CA207160"],"award-info":[{"award-number":["1U01CA207160"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.drudis.2021.10.014","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T08:37:08Z","timestamp":1635323828000},"page":"490-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Knowledge-based approaches to drug discovery for rare diseases"],"prefix":"10.1016","volume":"27","author":[{"given":"Vinicius M.","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Pervitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Thieme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Capuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rada","family":"Chirkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene N.","family":"Muratov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Tropsha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.10.014_b0005","unstructured":"NIH. FAQs About Rare Diseases | Genetic and Rare Diseases Information Center (GARD) \u2013 an NCATS Program. https:\/\/rarediseases.info.nih.gov\/diseases\/pages\/31\/faqs-about-rare-diseases [accessed October 21, 2021]."},{"issue":"2","key":"10.1016\/j.drudis.2021.10.014_b0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41588-019-0552-2","article-title":"A call for global action for rare diseases in Africa","volume":"52","author":"Baynam","year":"2020","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.drudis.2021.10.014_b0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41587-021-00945-0","article-title":"A call to arms against ultra-rare diseases","volume":"39","author":"Crooke","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2021.10.014_b0025","unstructured":"WHO. Neglected tropical diseases. www.who.int\/news-room\/q-a-detail\/neglected-tropical-diseases [accessed October 21, 2021]."},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13023-014-0195-4","article-title":"Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints","volume":"10","author":"Kakkis","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2021.10.014_b0035","unstructured":"Institute of Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington (DC): National Academies Press; 2010."},{"key":"10.1016\/j.drudis.2021.10.014_b0040","unstructured":"FDA. Developing products for rare diseases and conditions. www.fda.gov\/industry\/developing-products-rare-diseases-conditions [accessed October 21, 2021]."},{"key":"10.1016\/j.drudis.2021.10.014_b0045","unstructured":"PhRMA. Biopharmaceutical research industry profile. http:\/\/phrma.org\/sites\/default\/files\/pdf\/biopharmaceutical-industry-profile.pdf [accessed October 21, 2021]."},{"issue":"171","key":"10.1016\/j.drudis.2021.10.014_b0050","doi-asserted-by":"crossref","first-page":"171cm1","DOI":"10.1126\/scitranslmed.3003505","article-title":"An end to the myth: there is no drug development pipeline","volume":"5","author":"Baxter","year":"2013","journal-title":"Sci Transl Med"},{"issue":"7\u20138","key":"10.1016\/j.drudis.2021.10.014_b0055","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drudis.2011.02.016","article-title":"In silico repositioning of approved drugs for rare and neglected diseases","volume":"16","author":"Ekins","year":"2011","journal-title":"Drug Discov Today"},{"issue":"8","key":"10.1016\/j.drudis.2021.10.014_b0060","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"7607","key":"10.1016\/j.drudis.2021.10.014_b0065","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.drudis.2021.10.014_b0075","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2165\/00003495-199957060-00015","article-title":"Sildenafil","volume":"57","author":"Langtry","year":"1999","journal-title":"Drugs"},{"issue":"9423","key":"10.1016\/j.drudis.2021.10.014_b0080","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.drudis.2021.10.014_b0085","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41563-019-0338-z","article-title":"Exploiting machine learning for end-to-end drug discovery and development","volume":"18","author":"Ekins","year":"2019","journal-title":"Nat Mater"},{"key":"10.1016\/j.drudis.2021.10.014_b0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jbi.2017.08.011","article-title":"Literature based discovery: models, methods, and trends","volume":"74","author":"Henry","year":"2017","journal-title":"J Biomed Inform"},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12859-018-2167-5","article-title":"SemaTyP: a knowledge graph based literature mining method for drug discovery","volume":"19","author":"Sang","year":"2018","journal-title":"BMC Bioinformatics"},{"issue":"9769","key":"10.1016\/j.drudis.2021.10.014_b0100","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.drudis.2021.10.014_b0105","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/ajmg.a.38326","article-title":"Drug discovery and development for rare genetic disorders","volume":"173","author":"Sun","year":"2017","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.drudis.2021.10.014_b0110","unstructured":"PhRMA. Biopharmaceutical research and development: the process behind new medicines. http:\/\/phrma-docs.phrma.org\/sites\/default\/files\/pdf\/rd_brochure_022307.pdf [accessed October 21, 2021]."},{"issue":"4","key":"10.1016\/j.drudis.2021.10.014_b0115","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/ajmg.a.38413","article-title":"Challenges of developing and conducting clinical trials in rare disorders","volume":"176","author":"Kempf","year":"2018","journal-title":"Am J Med Genet Part A"},{"issue":"6","key":"10.1016\/j.drudis.2021.10.014_b0120","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1586\/ecp.09.40","article-title":"Challenges in conducting clinical trials in children: approaches for improving performance","volume":"2","author":"Kern","year":"2009","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.drudis.2021.10.014_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100075","article-title":"Biologics vs. small molecules: drug costs and patient access","volume":"9","author":"Makurvet","year":"2021","journal-title":"Med Drug Discov"},{"issue":"4","key":"10.1016\/j.drudis.2021.10.014_b0130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.drudis.2014.09.003","article-title":"An overview of FDA-approved biologics medicines","volume":"20","author":"Kinch","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2021.10.014_b0135","unstructured":"Growth hormone therapy in osteogenesis imperfecta. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00001305 [accessed October 21, 2021]."},{"key":"10.1016\/j.drudis.2021.10.014_b0140","unstructured":"Safety evaluation of Cellavita HD administered intravenously in participants with Huntington\u2019s disease (SAVE-DH). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02728115 [accessed October 21, 2021]."},{"issue":"7","key":"10.1016\/j.drudis.2021.10.014_b0145","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2015-09-618587","article-title":"Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease","volume":"127","author":"Hoban","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.10.014_b0150","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11095-018-2481-7","article-title":"Doing It All - How Families Are Reshaping Rare Disease Research","volume":"35","author":"Ekins","year":"2018","journal-title":"Pharm Res"},{"key":"10.1016\/j.drudis.2021.10.014_b0155","unstructured":"CBO. Research and development in the pharmaceutical industry. www.cbo.gov\/publication\/57126 [accessed October 21, 2021]."},{"key":"10.1016\/j.drudis.2021.10.014_b0160","unstructured":"Tindera M. A billionaire\u2019s dying wish: a $10 million prize to fight brain diseases. Forbes. www.forbes.com\/sites\/michelatindera\/2018\/11\/06\/a-billionaires-dying-wish-a-10-million-prize-to-fight-brain-diseases [accessed October 21, 2021]."},{"key":"10.1016\/j.drudis.2021.10.014_b0165","unstructured":"Rare Disease Clinical Research Network. www.rarediseasesnetwork.org\/diseases [accessed October 21, 2021]."},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cts.12500","article-title":"Future of rare diseases research 2017\u20132027: an IRDiRC perspective","volume":"11","author":"Austin","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.drudis.2021.10.014_b0175","unstructured":"PhrMA. A decade of innovation in rare diseases: 2005 to 2015. http:\/\/phrma-docs.phrma.org\/sites\/default\/files\/pdf\/PhRMA-Decade-of-Innovation-Rare-Diseases.pdf [accessed October 21, 2021]."},{"issue":"5","key":"10.1016\/j.drudis.2021.10.014_b0180","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1039\/C6MD00129G","article-title":"The evolution of drug discovery: from phenotypes to targets, and back","volume":"7","author":"Al-Ali","year":"2016","journal-title":"Medchemcomm"},{"key":"10.1016\/j.drudis.2021.10.014_b0185","unstructured":"AveXis receives FDA approval for Zolgensma\u00ae, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA). Novartis. www.novartis.com\/news\/media-releases\/avexis-receives-fda-approval-zolgensma-first-and-only-gene-therapy-pediatric-patients-spinal-muscular-atrophy-sma [accessed October 21, 2021]."},{"issue":"5","key":"10.1016\/j.drudis.2021.10.014_b0190","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ahg.12031","article-title":"Spinal muscular atrophy: from gene discovery to clinical trials","volume":"77","author":"Nurputra","year":"2013","journal-title":"Ann Hum Genet"},{"issue":"7","key":"10.1016\/j.drudis.2021.10.014_b0195","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.tig.2018.04.004","article-title":"Genetic-driven druggable target identification and validation","volume":"34","author":"Floris","year":"2018","journal-title":"Trends Genet"},{"issue":"19","key":"10.1016\/j.drudis.2021.10.014_b0200","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.10.014_b0205","unstructured":"Vertex Pharmaceuticals. A timeline: Vertex is committed to advances in cystic fibrosis (Infographic). www.vrtx.com\/about-us\/timeline-vertex-committed-advances-cystic-fibrosis-infographic\/ [accessed October 21, 2021]."},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0210","first-page":"8","article-title":"Ivacaftor: a novel gene-based therapeutic approach for cystic fibrosis","volume":"18","author":"Condren","year":"2013","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.drudis.2021.10.014_b0215","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.drudis.2021.10.014_b0220","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nbt.3787","article-title":"Industrializing rare disease therapy discovery and development","volume":"35","author":"Ekins","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2021.10.014_b0225","doi-asserted-by":"crossref","first-page":"261","DOI":"10.12688\/f1000research.5564.1","article-title":"Collaboration for rare disease drug discovery research","volume":"3","author":"Litterman","year":"2014","journal-title":"F1000Research"},{"key":"10.1016\/j.drudis.2021.10.014_b0230","unstructured":"ALD Connect. The Myelin Project. https:\/\/aldconnect.org\/about-us\/the-myelin-project\/ [accessed October 21, 2021]."},{"key":"10.1016\/j.drudis.2021.10.014_b0235","series-title":"Genes and Disease","author":"National Center for Biotechnology Information","year":"1998"},{"issue":"7","key":"10.1016\/j.drudis.2021.10.014_b0240","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archneur.62.7.1073","article-title":"Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo\u2019s oil","volume":"62","author":"Moser","year":"2005","journal-title":"Arch Neurol"},{"issue":"13","key":"10.1016\/j.drudis.2021.10.014_b0245","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1016\/j.bmcl.2017.05.010","article-title":"Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-\u03b2-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease","volume":"27","author":"Bi","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2021.10.014_b0250","unstructured":"Patton M, Rosenblatt G, Byrd WE, Might M. mediKanren: a system for bio-medical reasoning. In: 25th ACM SIGPLAN International Conference on Functional Programming. https:\/\/icfp20.sigplan.org\/details\/minikanren-2020-papers\/10\/mediKanren-A-System-for-Bio-medical-Reasoning [accessed October 21, 2021]."},{"key":"10.1016\/j.drudis.2021.10.014_b0255","unstructured":"NewsWise. Diagnosis in 2.127 seconds: solving a years-long vomiting mystery using AI, research and brain power. www.newswise.com\/articles\/diagnosis-in-2-127-seconds-solving-a-years-long-vomiting-mystery-using-ai-research-and-brain-power [accessed October 21, 2021]."},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0260","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13023-018-0990-4","article-title":"Estimating the clinical cost of drug development for orphan versus non-orphan drugs","volume":"14","author":"Jayasundara","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.drudis.2021.10.014_b0265","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.drudis.2018.11.022","article-title":"The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions","volume":"24","author":"Polamreddy","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2021.10.014_b0270","doi-asserted-by":"crossref","first-page":"6378137","DOI":"10.1155\/2016\/6378137","article-title":"Drug repurposing is a new opportunity for developing drugs against neuropsychiatric disorders","volume":"2016","author":"Lee","year":"2016","journal-title":"Schizophr Res Treatment"},{"issue":"3","key":"10.1016\/j.drudis.2021.10.014_b0275","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.drudis.2018.01.018","article-title":"A bibliometric review of drug repurposing","volume":"23","author":"Baker","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2021.10.014_b0280","series-title":"Approaching Complex Diseases. Human Perspectives in Health Sciences and Technology","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-030-32857-3_4","article-title":"Mining complex biomedical literature for actionable knowledge on rare diseases","author":"Alves","year":"2020"},{"issue":"4","key":"10.1016\/j.drudis.2021.10.014_b0285","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jbi.2010.03.008","article-title":"Mining connections between chemicals, proteins, and diseases extracted from Medline annotations","volume":"43","author":"Baker","year":"2010","journal-title":"J Biomed Inform"},{"issue":"D1","key":"10.1016\/j.drudis.2021.10.014_b0290","doi-asserted-by":"crossref","first-page":"D877","DOI":"10.1093\/nar\/gkw1012","article-title":"MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search","volume":"45","author":"Rappaport","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"10.1016\/j.drudis.2021.10.014_b0295","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"10.1016\/j.drudis.2021.10.014_b0300","doi-asserted-by":"crossref","first-page":"D901","DOI":"10.1093\/nar\/gkm958","article-title":"DrugBank: a knowledgebase for drugs, drug actions and drug targets","volume":"36","author":"Wishart","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2021.10.014_b0305","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1128\/JVI.03156-14","article-title":"Interaction between TIM-1 and NPC1 is important for cellular entry of Ebola virus","volume":"89","author":"Kuroda","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2021.10.014_b0310","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by design: a medicinal chemist\u2019s perspective on multitargeting compounds","volume":"62","author":"Proschak","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2021.10.014_b0315","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2021.10.014_b0320","unstructured":"Evox Therapeutics signs multi-target rare disease collaboration with Takeda - Global Genes. https:\/\/globalgenes.org\/2020\/03\/26\/evox-therapeutics-signs-multi-target-rare-disease-collaboration-with-takeda\/ [accessed October 21, 2021]."},{"key":"10.1016\/j.drudis.2021.10.014_b0325","doi-asserted-by":"crossref","unstructured":"Pierzynowska K, Kami\u0144ska T, W\u0119grzyn G. One drug to treat many diseases: unlocking the economic trap of rare diseases. Metab Brain Dis 2020 358 2020; 35: 1237\u20131240.","DOI":"10.1007\/s11011-020-00617-z"},{"issue":"D1","key":"10.1016\/j.drudis.2021.10.014_b0330","doi-asserted-by":"crossref","first-page":"D995","DOI":"10.1093\/nar\/gkw1072","article-title":"Pharos: collating protein information to shed light on the druggable genome","volume":"45","author":"Nguyen","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"10.1016\/j.drudis.2021.10.014_b0335","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"10.1016\/j.drudis.2021.10.014_b0340","doi-asserted-by":"crossref","first-page":"D789","DOI":"10.1093\/nar\/gku1205","article-title":"OMIM.org: Online Mendelian Inheritance in Man (OMIM\u00ae), an online catalog of human genes and genetic disorders","volume":"43","author":"Amberger","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2021.10.014_b0345","first-page":"195","article-title":"Rare diseases: drug discovery and informatics resource. Interdiscip Sci Comput","volume":"10","author":"Zhao","year":"2018","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0350","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13023-018-0936-x","article-title":"From scientific discovery to treatments for rare diseases - the view from the National Center for Advancing Translational Sciences \u2013 Office of Rare Diseases Research","volume":"13","author":"Kaufmann","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2021.10.014_b0355","doi-asserted-by":"crossref","unstructured":"Fourches D, Muratov E, Tropsha A. Curation of chemogenomics data. Nat Chem Biol 2015;11:535.","DOI":"10.1038\/nchembio.1881"},{"key":"10.1016\/j.drudis.2021.10.014_b0360","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12911-018-0621-y","article-title":"Utility of social media and crowd-intelligence data for pharmacovigilance: a scoping review","volume":"18","author":"Tricco","year":"2018","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.drudis.2021.10.014_b0365","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.7393","article-title":"Enhancing seasonal influenza surveillance: topic analysis of widely used medicinal drugs using Twitter data","volume":"19","author":"Kagashe","year":"2017","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.drudis.2021.10.014_b0370","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.clinthera.2017.08.016","article-title":"The use of social media in orphan drug development","volume":"39","author":"Milne","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.drudis.2021.10.014_b0375","series-title":"Rare Diseases Epidemiology: Update and Overview. Advances in Experimental Medicine and Biology","first-page":"165","article-title":"Preparing data at the source to Foster interoperability across rare disease resources","author":"Roos","year":"2017"},{"key":"10.1016\/j.drudis.2021.10.014_b0380","series-title":"Graph Databases","author":"Robinson","year":"2013"},{"key":"10.1016\/j.drudis.2021.10.014_b0385","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13326-017-0127-z","article-title":"Ontological interpretation of biomedical database content","volume":"8","author":"Santana da Silva","year":"2017","journal-title":"J Biomed Semantics"},{"key":"10.1016\/j.drudis.2021.10.014_b0390","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.knosys.2018.03.022","article-title":"Graph embedding techniques, applications, and performance: a survey","volume":"151","author":"Goyal","year":"2018","journal-title":"Knowledge-Based Syst"},{"key":"10.1016\/j.drudis.2021.10.014_b0395","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00357-019-09314-8","article-title":"Clustering large datasets by merging K-means solutions","volume":"37","author":"Melnykov","year":"2020","journal-title":"J Classif"},{"key":"10.1016\/j.drudis.2021.10.014_b0400","series-title":"Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining","first-page":"855","article-title":"Node2vec: scalable feature learning for networks","author":"Grover","year":"2016"},{"key":"10.1016\/j.drudis.2021.10.014_b0405","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1021\/acs.jcim.0c01301","article-title":"Informatics for chemistry, biology, and biomedical sciences","volume":"61","author":"L\u00f3pez-L\u00f3pez","year":"2021","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2021.10.014_b0410","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.hlpt.2014.08.007","article-title":"Rare Disease Research Roadmap: navigating the bioinformatics and translational challenges for improved patient health outcomes","volume":"3","author":"Bellgard","year":"2014","journal-title":"Heal Policy Technol"},{"issue":"2","key":"10.1016\/j.drudis.2021.10.014_b0415","doi-asserted-by":"crossref","first-page":"lqaa032","DOI":"10.1093\/nargab\/lqaa032","article-title":"Phen2Gene: rapid phenotype-driven gene prioritization for rare diseases","volume":"2","author":"Zhao","year":"2020","journal-title":"NAR Genomics Bioinforma"},{"key":"10.1016\/j.drudis.2021.10.014_b0420","doi-asserted-by":"crossref","unstructured":"Schork NJ. Genetics of Complex Disease. Am J Respir Crit Care Med 1997;156(4):S103\u2013S109.","DOI":"10.1164\/ajrccm.156.4.12-tac-5"},{"key":"10.1016\/j.drudis.2021.10.014_b0425","unstructured":"GeneCards Version 5.4. www.genecards.org\/ [accessed October 21, 2021]."},{"key":"10.1016\/j.drudis.2021.10.014_b0430","series-title":"Chemoinformatics: Basic Concepts and Methods","year":"2018"},{"issue":"20","key":"10.1016\/j.drudis.2021.10.014_b0435","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/cphc.202000518","article-title":"Chemistry in times of artificial intelligence","volume":"21","author":"Gasteiger","year":"2020","journal-title":"ChemPhysChem"},{"issue":"12","key":"10.1016\/j.drudis.2021.10.014_b0440","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1021\/jm4004285","article-title":"QSAR modeling: where have you been? Where are you going to?","volume":"57","author":"Cherkasov","year":"2014","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.drudis.2021.10.014_b0445","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s10822-014-9762-y","article-title":"Bigger data, collaborative tools and the future of predictive drug discovery","volume":"28","author":"Ekins","year":"2014","journal-title":"J Comput Aided Mol Des"},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2014.88","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs","volume":"3","author":"Kouznetsova","year":"2014","journal-title":"Emerg Microbes Infect"},{"issue":"8","key":"10.1016\/j.drudis.2021.10.014_b0455","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1021\/acs.jmedchem.8b00035","article-title":"Computer-aided discovery and characterization of novel Ebola virus inhibitors","volume":"61","author":"Capuzzi","year":"2018","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.drudis.2021.10.014_b0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060579","article-title":"A systematic screen of FDA-approved drugs for inhibitors of biological threat agents","volume":"8","author":"Madrid","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.drudis.2021.10.014_b0465","doi-asserted-by":"crossref","first-page":"e01142","DOI":"10.1128\/AAC.01142-19","article-title":"Repurposing quinacrine against Ebola virus infection in vivo","volume":"63","author":"Lane","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0470","doi-asserted-by":"crossref","first-page":"12982","DOI":"10.1038\/s41598-020-70026-w","article-title":"Synergistic drug combinations and machine learning for drug repurposing in chordoma","volume":"10","author":"Anderson","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0475","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jbi.2009.08.006","article-title":"What is biomedical informatics?","volume":"43","author":"Bernstam","year":"2010","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.drudis.2021.10.014_b0480","series-title":"Guide to Health Informatics","author":"Coiera","year":"2015"},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0485","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1109\/JBHI.2016.2636665","article-title":"Deep learning for health informatics","volume":"21","author":"Ravi","year":"2017","journal-title":"IEEE J Biomed Heal Informatics"},{"issue":"2","key":"10.1016\/j.drudis.2021.10.014_b0490","article-title":"Diagnostic needs for rare diseases and shared prediagnostic phenomena: results of a German-wide expert Delphi survey","volume":"12","author":"Bl\u00f6b","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2021.10.014_b0495","first-page":"340","article-title":"Tremblay Volv Global Lausanne Switzerland M. Learning to Identify rare disease patients from electronic health records","author":"Colbaugh","year":"2018","journal-title":"AMIA Annu Symp Proc"},{"issue":"4","key":"10.1016\/j.drudis.2021.10.014_b0500","doi-asserted-by":"crossref","DOI":"10.2196\/11301","article-title":"Utilization of electronic medical records and biomedical literature to support the diagnosis of rare diseases using data fusion and collaborative filtering approaches","volume":"6","author":"Shen","year":"2018","journal-title":"JMIR Med Informatics"},{"issue":"7553","key":"10.1016\/j.drudis.2021.10.014_b0505","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature14539","article-title":"Deep learning","volume":"521","author":"LeCun","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.10.014_b0510","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1007\/s11095-016-2029-7","article-title":"The next era: deep learning in pharmaceutical research","volume":"33","author":"Ekins","year":"2016","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.drudis.2021.10.014_b0515","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/bib\/bbx044","article-title":"Deep learning for healthcare: review, opportunities and challenges","volume":"19","author":"Miotto","year":"2017","journal-title":"Brief Bioinform"},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0520","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41591-018-0279-0","article-title":"Identifying facial phenotypes of genetic disorders using deep learning","volume":"25","author":"Gurovich","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2021.10.014_b0525","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3389\/fgene.2018.00587","article-title":"RDAD: a machine learning system to support phenotype-based rare disease diagnosis","volume":"9","author":"Jia","year":"2018","journal-title":"Front Genet"},{"issue":"12","key":"10.1016\/j.drudis.2021.10.014_b0530","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1038\/s41436-019-0566-2","article-title":"PEDIA: prioritization of exome data by image analysis","volume":"21","author":"Hsieh","year":"2019","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0535","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41746-019-0191-0","article-title":"Artificial intelligence for precision medicine in neurodevelopmental disorders","volume":"2","author":"Uddin","year":"2019","journal-title":"NPJ Digit Med"},{"issue":"1\u20132","key":"10.1016\/j.drudis.2021.10.014_b0540","first-page":"1","article-title":"Knowledge-based biomedical data science","volume":"1","author":"Hunter","year":"2017","journal-title":"Data Sci"},{"key":"10.1016\/j.drudis.2021.10.014_b0545","doi-asserted-by":"crossref","first-page":"baw145","DOI":"10.1093\/database\/baw145","article-title":"Text mining resources for the life sciences","volume":"2016","author":"Przyby\u0142a","year":"2016","journal-title":"Database"},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0550","first-page":"29","article-title":"Medical literature as a potential source of new knowledge","volume":"78","author":"Swanson","year":"1990","journal-title":"BMLA"},{"issue":"2","key":"10.1016\/j.drudis.2021.10.014_b0555","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.techfore.2007.11.007","article-title":"Literature-Related Discovery (LRD): potential treatments for Parkinson\u2019s Disease","volume":"75","author":"Kostoff","year":"2008","journal-title":"Technol Forecast Soc Change"},{"issue":"42","key":"10.1016\/j.drudis.2021.10.014_b0560","doi-asserted-by":"crossref","first-page":"10666","DOI":"10.1073\/pnas.1806643115","article-title":"Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2","volume":"115","author":"Choi","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.drudis.2021.10.014_b0565","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1021\/acs.jcim.7b00589","article-title":"Chemotext: a publicly available web server for mining drug\u2013target\u2013disease relationships in PubMed","volume":"58","author":"Capuzzi","year":"2018","journal-title":"J Chem Inf Model"},{"issue":"12","key":"10.1016\/j.drudis.2021.10.014_b0570","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1021\/acs.jcim.9b00683","article-title":"ROBOKOP KG and KGB: integrated knowledge graphs from federated sources","volume":"59","author":"Bizon","year":"2019","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2021.10.014_b0575","doi-asserted-by":"crossref","unstructured":"Hogan A, Blomqvist E, Cochez M, D\u2019Amato C, de Melo G, Gutierrez C, et al. Knowledge graphs. ACM Comput Surv 54(4):71:1\u201371:37","DOI":"10.1145\/3447772"},{"issue":"2","key":"10.1016\/j.drudis.2021.10.014_b0580","first-page":"69","article-title":"Knowledge-base verification","volume":"8","author":"Nguyen","year":"1987","journal-title":"AI Mag"},{"issue":"3","key":"10.1016\/j.drudis.2021.10.014_b0585","first-page":"489","article-title":"Knowledge graph refinement: a survey of approaches and evaluation methods","volume":"8","author":"Paulheim","year":"2017","journal-title":"Semant Web"},{"issue":"2","key":"10.1016\/j.drudis.2021.10.014_b0590","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CCO.0000000000000502","article-title":"Chordoma: update on disease, epidemiology, biology and medical therapies","volume":"31","author":"Frezza","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"10.1016\/j.drudis.2021.10.014_b0595","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.drudis.2021.10.014_b0600","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/BJ20150497","article-title":"Repurposing metformin: an old drug with new tricks in its binding pockets","volume":"471","author":"Pryor","year":"2015","journal-title":"Biochem J"},{"issue":"6","key":"10.1016\/j.drudis.2021.10.014_b0605","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014961","article-title":"Study protocol of a phase IB\/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours","volume":"7","author":"Molenaar","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.drudis.2021.10.014_b0610","unstructured":"Longhi A, Istituto Ortopedico Rizzoli. Metformin as maintenance therapy in patients with bone sarcoma and high risk of relapse. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04758000 [accessed October 21, 2021]."},{"issue":"1","key":"10.1016\/j.drudis.2021.10.014_b0615","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cbi.2014.03.013","article-title":"Involvement of catalase in the protective benefits of metformin in mice with oxidative liver injury","volume":"216","author":"Dai","year":"2014","journal-title":"Chem Biol Interact"},{"issue":"4","key":"10.1016\/j.drudis.2021.10.014_b0620","doi-asserted-by":"crossref","first-page":"C734","DOI":"10.1152\/ajpcell.00068.2020","article-title":"Skeletal tissue regulation by catalase overexpression in mitochondria","volume":"319","author":"Schreurs","year":"2020","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.drudis.2021.10.014_b0625","series-title":"Bone Cancer","first-page":"39","article-title":"Chapter 4 - Deregulation of osteoblast differentiation in primary bone cancers","author":"Marie","year":"2015"},{"key":"10.1016\/j.drudis.2021.10.014_b0630","doi-asserted-by":"crossref","unstructured":"Ehrhart F, Willighagen EL, Kutmon M, van Hoften M, Curfs LMG, Evelo CT. A resource to explore the discovery of rare diseases and their causative genes. Sci Data 2021 81 2021; 8(1): 1\u20138.","DOI":"10.1038\/s41597-021-00905-y"},{"key":"10.1016\/j.drudis.2021.10.014_b0635","unstructured":"Novartis. FDA approves Novartis Kesimpta\u00ae (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis. www.novartis.com\/news\/media-releases\/fda-approves-novartis-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-patients-relapsing-multiple-sclerosis [accessed October 21, 2021]."},{"issue":"15 Supplement","key":"10.1016\/j.drudis.2021.10.014_b0640","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1212\/WNL.96.15_supplement.4437","article-title":"Fenebrutinib demonstrates the highest potency of Bruton tyrosine kinase inhibitors (BTKis) in Phase 3 clinical development for multiple sclerosis (MS) (4437)","volume":"96","author":"Weber","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2021.10.014_b0645","unstructured":"FDA. FDA approves Ocaliva for rare, chronic liver disease. www.fda.gov\/news-events\/press-announcements\/fda-approves-ocaliva-rare-chronic-liver-disease [accessed October 21, 2021]."},{"issue":"6","key":"10.1016\/j.drudis.2021.10.014_b0650","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2021.10.014_b0655","unstructured":"Children's Hospital Medical Center, Cincinnati. Testing drug efficacy in cystic fibrosis through N-of-1 trials (Nof1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04580368 [accessed October 21, 2021]."},{"issue":"2","key":"10.1016\/j.drudis.2021.10.014_b0660","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40265-018-0861-2","article-title":"Emicizumab-kxwh: first global approval","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2021.10.014_b0665","unstructured":"BioMarin Pharmaceutical. Single-arm study to evaluate the efficacy and safety of valoctocogene roxaparvovec in hemophilia A patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03370913 [accessed October 21, 2021]."},{"issue":"10","key":"10.1016\/j.drudis.2021.10.014_b0670","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.drudis.2021.10.014_b0675","unstructured":"FDA. FDA approves oral treatment for spinal muscular atrophy. www.fda.gov\/news-events\/press-announcements\/fda-approves-oral-treatment-spinal-muscular-atrophy [accessed October 21, 2021]."},{"key":"10.1016\/j.drudis.2021.10.014_b0680","unstructured":"FDA. FDA approves first drug for spinal muscular atrophy. www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-spinal-muscular-atrophy [accessed October 21, 2021]."},{"key":"10.1016\/j.drudis.2021.10.014_b0685","unstructured":"An active treatment study of SRK-015 in patients with Type 2 or Type 3 spinal muscular atrophy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03921528 [accessed October 21, 2021]."},{"key":"10.1016\/j.drudis.2021.10.014_b0690","first-page":"CD001447","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"2002","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.drudis.2021.10.014_b0695","unstructured":"Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC\u2013NTF Cells in Patients With ALS (NurOwn). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02017912 [accessed October 21, 2021]."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621004529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621004529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:57:57Z","timestamp":1761224277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621004529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":139,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1359644621004529"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.10.014","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Knowledge-based approaches to drug discovery for rare diseases","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}